Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
暂无分享,去创建一个
[1] E. Heimer,et al. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. , 1992, Biochimica et biophysica acta.
[2] M. Sticherling,et al. Identification of an N-terminally truncated form of the chemokine RANTES and granulocyte-macrophage colony-stimulating factor as major eosinophil attractants released by cytokine-stimulated dermal fibroblasts. , 1996, Journal of immunology.
[3] F. Tan,et al. Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages. , 1995, American journal of respiratory cell and molecular biology.
[4] T. Honjo,et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1α (SDF-1α) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage , 1998 .
[5] H. Bernstein,et al. Immunolocalization of dipeptidyl aminopeptidase (DAP IV) in the developing human brain , 1987, International Journal of Developmental Neuroscience.
[6] P. Gaudreau,et al. Catabolism of rat growth hormone-releasing factor(1–29) amide in rat serum and liver , 1992, Peptides.
[7] Y. Misumi,et al. Identification of the active site residues in dipeptidyl peptidase IV by affinity labeling and site-directed mutagenesis. , 1992, Biochemistry.
[8] M. Harada,et al. IMMUNOHISTOCHEMICAL LOCALIZATION OF DIPEPTIDYL AMINOPEPTIDASE (DAP) IV IN THE RAT ENDOCRINE ORGANS , 1981 .
[9] R. Lucius,et al. Proline-specific proteases in cultivated neuronal and glial cells , 1990, Brain Research.
[10] E. De Clercq,et al. Processing by CD26/dipeptidyl‐peptidase IV reduces the chemotactic and anti‐HIV‐1 activity of stromal‐cell‐derived factor‐1α , 1998, FEBS letters.
[11] D. Drucker. Glucagon-Like Peptides , 1998, Diabetes.
[12] J. Huneau,et al. Metabolism of enterostatin in rat intestine, brain membranes, and serum: Differential involvement of proline-specific peptidases , 1995, Peptides.
[13] J. Schrezenmeir,et al. Biological activity of GLP-1-analogues with N-terminal modifications , 1999, Regulatory Peptides.
[14] Y. Misumi,et al. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. , 1992, Biochimica et biophysica acta.
[15] D. Drucker,et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV , 1997, Nature Biotechnology.
[16] R. Mentlein,et al. Proline-specific dipeptidyl peptidase from the blue blowfly Calliphora vicina hydrolyzes in vitro the ecdysiostatic peptide trypsin-modulating oostatic factor (Neb-TMOF). , 1998, Archives of insect biochemistry and physiology.
[17] J. Pesquero,et al. Bradykinin metabolism pathway in the rat pulmonary circulation , 1992, Journal of hypertension.
[18] Y. Misumi,et al. Selective cell-surface expression of dipeptidyl peptidase IV with mutations at the active site sequence. , 1992, Biochemical and biophysical research communications.
[19] R. Mentlein,et al. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. , 1978, FEBS letters.
[20] T. Hoffmann,et al. The N‐terminal X‐X‐Pro sequence of the HIV‐1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen‐induced proliferation of human T cells , 1996, FEBS letters.
[21] G. Opdenakker,et al. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. , 1998, Biochemistry.
[22] B. Gusterson,et al. Dipeptidyl peptidase iv expression identifies a functional sub‐population of breast fibroblasts , 1992, International journal of cancer.
[23] Ji Ming Wang,et al. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor , 1998, European journal of immunology.
[24] R. Pederson,et al. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.
[25] F. Naider,et al. Proline-dependent structural and biological properties of peptides and proteins. , 1993, Critical reviews in biochemistry and molecular biology.
[26] J. Mcdonald. Mammalian Proteases : A Glossary and Bibliography , 1986 .
[27] T. Kubiak,et al. In vitro metabolic degradation of a bovine growth hormone-releasing factor analog Leu27-bGRF(1-29)NH2 in bovine and porcine plasma. Correlation with plasma dipeptidylpeptidase activity. , 1989, Drug metabolism and disposition: the biological fate of chemicals.
[28] J. Holst,et al. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. , 1998, Diabetes.
[29] Lianguo Wang,et al. Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. , 1992, The Journal of pharmacology and experimental therapeutics.
[30] H. Tinneberg,et al. Influence of Pregnancy on Dipeptidyl Peptidase IV Activity (CD 26 Leukocyte Differentiation Antigen) of Circulating Lymphocytes , 1991, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.
[31] M. Grim,et al. Localization of dipeptidylpeptidase IV and alkaline phosphatase in developing spinal cord meninges and peripheral nerve coverings of the rat , 1990, International Journal of Developmental Neuroscience.
[32] R. Pederson,et al. Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide , 1998, Diabetes.
[33] J. Holst,et al. Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.
[34] C. Morimoto,et al. Negative regulation of the anti‐human immunodeficiency virus and chemotactic activity of human stromal cell‐derived factor 1α by CD26/dipeptidyl peptidase IV , 1998, FEBS letters.
[35] E. De Clercq,et al. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. , 1998, Journal of immunology.
[36] Terry D. Lee,et al. A new molecular form of PYY: Structural characterization of human PYY(3–36) and PYY(1–36) , 1989, Peptides.
[37] L. Thim,et al. Neuropeptide Y and neuropeptide Y 3–36: isolation from human pancreatic endocrine tumours , 1993, Regulatory Peptides.
[38] B. Fleischer,et al. Dipeptidyl‐peptidase IV/CD26 on T cells: analysis of an alternative T‐cell activation pathway , 1998, Immunological reviews.
[39] E. Sadoun,et al. Metabolism of substance P and neurokinin A by human vascular endothelium and smooth muscle , 1994, Peptides.
[40] A. Feller,et al. Processing of pro-colipase and trypsinogen by pancreatic dipeptidyl peptidase IV. , 1986, Biomedica biochimica acta.
[41] R. Burcelin,et al. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. , 1999, Metabolism: clinical and experimental.
[42] W. T. Chen,et al. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. , 1997, Biochimica et biophysica acta.
[43] A. Fersht. Enzyme structure and mechanism , 1977 .
[44] W. Creutzfeldt,et al. Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39. , 1987, Endocrinology.
[45] T. Kato,et al. Successive cleavage of N-terminal Arg1--Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin, by X-Pro dipeptidyl-aminopeptidase. , 1978, Biochimica et biophysica acta.
[46] Daniel Grandt,et al. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV , 1993, Regulatory Peptides.
[47] R. Mentlein,et al. Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells , 1996, Peptides.
[48] A. Mallet,et al. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. , 1998, Journal of immunology.
[49] B. Humbel,et al. Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney. , 1992, Acta histochemica.
[50] E. Burcher,et al. Tachykinin Receptors: A Radioligand Binding Perspective , 1993, Journal of neurochemistry.
[51] L. Frohman,et al. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. , 1989, The Journal of clinical investigation.
[52] M. Ditto,et al. Regulation of the Receptor Specificity and Function of the Chemokine RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) by Dipeptidyl Peptidase IV (CD26)-mediated Cleavage , 1997, The Journal of experimental medicine.
[53] R. Wenthold,et al. Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[54] D. Drucker,et al. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. , 1997, American journal of physiology. Gastrointestinal and liver physiology.
[55] S. Mizutani,et al. Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme , 1991, Peptides.
[56] W. Reutter,et al. Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens , 1998, FEBS letters.
[57] J. Holst,et al. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. , 1998, Diabetes.
[58] R. Mentlein,et al. Prolyl aminopeptidase from rat brain and kidney. Action on peptides and identification as leucyl aminopeptidase. , 1990, European journal of biochemistry.
[59] D. Proud,et al. Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides. , 1992, The Journal of clinical investigation.
[60] R. Pederson,et al. Investigation of Glucose-dependent Insulinotropic Polypeptide(1-42) and Glucagon-like Peptide-1-(7-36) Degradation in Vitro by Dipeptidyl Peptidase IV Using Matrix-assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry , 1996, The Journal of Biological Chemistry.
[61] S. Henriksen,et al. Transcripts encoding a neural membrane CD26 peptidase-like protein are stimulated by synaptic activity. , 1994, Brain research. Molecular brain research.
[62] G. Püschel,et al. Isolation and characterization of dipeptidyl peptidase IV from human placenta. , 1982, European journal of biochemistry.
[63] R. Bodnar,et al. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV , 1999, Brain Research.
[64] Dominique Schols,et al. Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV , 1998, The Journal of Biological Chemistry.
[65] R. Mentlein,et al. The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. , 1990, Biological chemistry Hoppe-Seyler.
[66] W. Rascher,et al. Neuropeptide Y 3–36 is an endogenous ligand selective for Y2 receptors , 1996, Regulatory Peptides.
[67] D. Marguet,et al. Identification of serine 624, aspartic acid 702, and histidine 734 as the catalytic triad residues of mouse dipeptidyl-peptidase IV (CD26). A member of a novel family of nonclassical serine hydrolases. , 1993, The Journal of biological chemistry.
[68] B. Bauvois,et al. Characterization of specific proteases associated with the surface of human skin fibroblasts, and their modulation in pathology , 1992, Journal of cellular physiology.
[69] J. Neefs,et al. Isolation and Expression of Novel Human Glutamate Carboxypeptidases with N-Acetylated α-Linked Acidic Dipeptidase and Dipeptidyl Peptidase IV Activity* , 1999, The Journal of Biological Chemistry.
[70] P. Allavena,et al. Truncation of Macrophage-derived Chemokine by CD26/ Dipeptidyl-Peptidase IV beyond Its Predicted Cleavage Site Affects Chemotactic Activity and CC Chemokine Receptor 4 Interaction* , 1999, The Journal of Biological Chemistry.
[71] P. Proost,et al. Isolation of the CXC chemokines ENA‐78, GROα and GROγ from tumor cells and leukocytes reveals NH2‐terminal heterogeneity , 1999 .
[72] E. De Clercq,et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. , 1999, Journal of immunology.
[73] R. Ludwig,et al. Metabolism of neuropeptide Y and calcitonin gene-related peptide by cultivated neurons and glial cells. , 1996, Brain research. Molecular brain research.
[74] L. E. Lantry,et al. Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts , 1996, Peptides.
[75] R. Mentlein,et al. Proline residues in the maturation and degradation of peptide hormones and neuropeptides , 1988, FEBS letters.
[76] D. Schuppan,et al. The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. , 1995, Biochemical and biophysical research communications.
[77] T. Kubiak,et al. Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity? , 1993, Biochimica et biophysica acta.
[78] J. Rahfeld,et al. Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? , 1991, Biochimica et biophysica acta.
[79] B. Gallwitz,et al. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.
[80] J. Gum,et al. Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter. , 1995, The Biochemical journal.
[81] K. Imai,et al. Human luteal cells express dipeptidyl peptidase IV on the cell surface. , 1992, The Journal of clinical endocrinology and metabolism.
[82] J. Holst,et al. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.
[83] B. Göke,et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides , 1995, Regulatory Peptides.
[84] E. De Clercq,et al. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. , 1998, Antiviral research.
[85] V. Mutt,et al. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP) , 1981, FEBS letters.
[86] J. Holst,et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. , 1996, The American journal of physiology.
[87] J. Blanco,et al. Dipeptidyl-peptidase IV-beta, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity. , 1996, European journal of biochemistry.
[88] Neil D. Rawlings,et al. Handbook of proteolytic enzymes , 1998 .
[89] C. Beglinger,et al. Two molecular forms of Peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36 , 1994, Regulatory Peptides.
[90] W. T. Chen,et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. , 1998, Circulation research.
[91] A. Feller,et al. Dipeptidyl peptidase IV as a new surface marker for a subpopulation of human T-lymphocytes. , 1984, Cellular immunology.
[92] K. Blennow,et al. Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometry , 1998, Peptides.
[93] Chika Morimoto,et al. The structure and function of CD26 in the T‐cell immune response , 1998, Immunological reviews.
[94] Greet Vanhoof,et al. Proline motifs in peptides and their biological processing , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[95] R. Mentlein,et al. Complementary action of dipeptidyl peptidase IV and aminopeptidase M in the digestion of β-casein , 1986, Journal of Dairy Research.
[96] S. Whitebread,et al. A receptor subtype involved in neuropeptide-Y-induced food intake , 1996, Nature.
[97] J. Holst,et al. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity , 1998, Diabetologia.
[98] W. Hong,et al. Molecular dissection of the NH2-terminal signal/anchor sequence of rat dipeptidyl peptidase IV , 1990, The Journal of cell biology.
[99] T. Hoffmann,et al. Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N‐terminal cytokine sequences , 1993, FEBS letters.
[100] G. Kreil. Processing of precursors by dipeptidylaminopeptidases: a case of molecular ticketing. , 1990, Trends in biochemical sciences.
[101] R. Mentlein,et al. Purification of Two Dipeptidyl Aminopeptidases II from Rat Brain and Their Action on Proline‐Containing Neuropeptides , 1989, Journal of neurochemistry.